Atrial Fibrillation Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Atrial Fibrillation stocks.

Atrial Fibrillation Stocks Recent News

Date Stock Title
Mar 18 MDT Two Days Left Until Medtronic plc (NYSE:MDT) Trades Ex-Dividend
Mar 18 MDT Medtronic's Ex-Dividend Date Is Thursday, Here's What You Need To Know
Mar 18 BMY Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
Mar 18 BMY Perspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment study
Mar 18 BMY Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Mar 18 MDT Here Are My Top Artificial Intelligence (AI) Stocks to Buy in March
Mar 17 MDT 20 Best Countries to Move to from USA
Mar 17 MDT Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT)
Mar 17 MDT 3 Companies With Strong Irish Operations
Mar 16 BMY Bristol Myers wins FDA AdCom backing for Abecma label expansion
Mar 15 BMY FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Mar 15 BMY Bristol Myers Squibb (BMY) Stock Moves -0.29%: What You Should Know
Mar 15 BMY UPDATE 1-US FDA panel unanimously backs expanded use of J&J's CAR-T therapy
Mar 15 BMY 20 States with the Highest Cancer Rates
Mar 15 BMY Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
Mar 15 BMY Bristol Myers cell therapy wins first-of-its-kind approval
Mar 15 BMY FDA approves expanded use of Bristol Myers CAR T-cell therapy
Mar 15 MDT Medtronic’s Sean Salmon on cardiovascular competition, carving out new markets
Mar 15 BMY UPDATE 2-US FDA expands use of Bristol Myers' cancer therapy
Mar 15 BMY U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Atrial Fibrillation

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.High blood pressure and valvular heart disease are the most common alterable risk factors for AF. Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. In the developing world valvular heart disease often occurs as a result of rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Other factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, half of cases are not associated with any of these risks. A diagnosis is made by feeling the pulse and may be confirmed using an electrocardiogram (ECG). A typical ECG in AF shows no P waves and an irregular ventricular rate.AF is often treated with medications to slow the heart rate to a near normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control). Electrical cardioversion can also be used to convert AF to a normal sinus rhythm and is often used emergently if the person is unstable. Ablation may prevent recurrence in some people. For those at low risk of stroke, no specific treatment is typically required, though aspirin or an anti-clotting medication may occasionally be considered. For those at more than low risk, an anti-clotting medication is typically recommended. Anti-clotting medications include warfarin and direct oral anticoagulants. Most people are at higher risk of stroke. While these medications reduce stroke risk, they increase rates of major bleeding.Atrial fibrillation is the most common serious abnormal heart rhythm. In Europe and North America, as of 2014, it affects about 2 to 3% of the population. This is an increase from 0.4 to 1% of the population around 2005. In the developing world, about 0.6% of males and 0.4% of females are affected. The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected. A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990. The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749. This was first documented by ECG in 1909 by Thomas Lewis.

Browse All Tags